WallStSmart

Churchill Capital Corp XI Class A Ordinary Shares (CCXI)vsGP-Act III Acquisition Corp. Class A Ordinary Share (GPAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GPAT leads profitability with a 0.0% profit margin vs 0.0%. GPAT earns a higher WallStSmart Score of 32/100 (F).

CCXI

Avoid

32

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 5.0

GPAT

Avoid

32

out of 100

Grade: F

Growth: 3.7Profit: 4.0Value: 4.7Quality: 5.3
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCXI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
549.0%10/10

Revenue surging 549.0% year-over-year

GPAT1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Areas to Watch

CCXI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-47.0%2/10

ROE of -47.0% — below average capital efficiency

Free Cash FlowQuality
$-26.53M2/10

Negative free cash flow — burning cash

GPAT4 concerns · Avg: 3.5/10
P/E RatioValuation
32.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Market CapQuality
$389.56M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : CCXI

The strongest argument for CCXI centers on Revenue Growth. Revenue growth of 549.0% demonstrates continued momentum.

Bull Case : GPAT

The strongest argument for GPAT centers on Debt/Equity.

Bear Case : CCXI

The primary concerns for CCXI are EPS Growth, Profit Margin, Return on Equity.

Bear Case : GPAT

The primary concerns for GPAT are P/E Ratio, Revenue Growth, Market Cap.

Key Dynamics to Monitor

CCXI profiles as a hypergrowth stock while GPAT is a value play — different risk/reward profiles.

CCXI is growing revenue faster at 549.0% — sustainability is the question.

GPAT generates stronger free cash flow (10,832), providing more financial flexibility.

Monitor SHELL COMPANIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CCXI scores higher overall (32/100 vs 32/100) and 549.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Churchill Capital Corp XI Class A Ordinary Shares

FINANCIAL SERVICES · SHELL COMPANIES · USA

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.

GP-Act III Acquisition Corp. Class A Ordinary Share

FINANCIAL SERVICES · SHELL COMPANIES · USA

GP-Act III Acquisition Corp. (GPAT) is a special purpose acquisition company (SPAC) dedicated to identifying and acquiring innovative growth-oriented firms primarily within the technology and consumer sectors. Backed by a seasoned management team, GPAT is strategically positioned to execute value-adding mergers and acquisitions that unlock significant shareholder value. By focusing on high-potential businesses that align with emerging trends, GPAT offers institutional investors a unique opportunity to capitalize on transformative market dynamics in rapidly evolving industries.

Visit Website →

Want to dig deeper into these stocks?